ADVERTISEMENT
Adding Metastasis-Directed Therapy for Oligometastatic Pancreas Cancer
Featuring Ethan Ludmir, MD
At the 2024 ASCO Gastrointestinal Cancers Symposium, Ethan Ludmir, MD, discusses results from the phase 2 EXTEND study, evaluating the addition of metastasis-directed therapy for oligometastatic pancreas cancer.
This study found, among patients with oligometastatic pancreatic ductal adenocarcinoma, the combination of metastasis-directed therapy plus systemic therapy was associated with improved progression-free survival compared with systemic therapy alone.
Source:
Ludmir EB, Sherry AD, Fellman BM, et al. Addition of metastasis-directed therapy to standard-of-care systemic therapy for oligometastatic pancreatic ductal adenocarcinoma (EXTEND): Results of a multicenter, randomized phase II trial. Presented at the 2024 ASCO Gastrointestinal Cancers Symposium; January 18-20, 2024; San Francisco, California. Abstract 603
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Visit the OLN Excellence Forums
Advertisement
Advertisement
Advertisement